Tesamorelin
Egrifta SV (tesamorelin) is a protein pharmaceutical. Tesamorelin was first approved as Egrifta on 2010-11-10. It is used to treat hiv-associated lipodystrophy syndrome in the USA. The pharmaceutical is active against growth hormone-releasing hormone receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Egrifta sv (discontinued: Egrifta sv)
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Tesamorelin
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Egrifta SV | tesamorelin | Theratechnologies | N-22505 RX | 2011-11-29 | 1 products |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| egrifta sv | Biologic Licensing Application | 2024-02-29 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| hiv-associated lipodystrophy syndrome | EFO_1001348 | D039682 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
23 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lipodystrophy | D008060 | HP_0009125 | E88.1 | — | — | 2 | 1 | 4 | 7 |
| Hiv | D006678 | — | — | 1 | — | — | 1 | 3 | 5 |
| Hiv-associated lipodystrophy syndrome | D039682 | EFO_1001348 | — | — | — | — | 1 | 2 | 3 |
| Laron syndrome | D046150 | Orphanet_633 | E34.321 | — | 1 | — | 1 | — | 2 |
| Body composition | D001823 | — | — | — | — | — | 1 | — | 1 |
| Retinal diseases | D012164 | HP_0000479 | H35.9 | — | — | — | 1 | — | 1 |
| Diabetic retinopathy | D003930 | EFO_0003770 | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | — | 1 | 2 | — | 2 | 5 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Abdominal obesity | D056128 | HP_0001956 | — | — | 3 | — | — | 1 | 4 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | 2 | — | — | 1 | 3 |
| Cognitive dysfunction | D060825 | HP_0001268 | G31.84 | 1 | 2 | — | — | — | 3 |
| Liver diseases | D008107 | HP_0002910 | K70-K77 | — | 1 | — | — | 1 | 2 |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | — | 1 | — | — | 1 | 2 |
| Fatty liver | D005234 | EFO_0003934 | — | — | 1 | — | — | 1 | 2 |
| Aging | D000375 | GO_0007568 | R41.81 | — | 2 | — | — | — | 2 |
| Wounds and injuries | D014947 | — | T14.8 | — | 2 | — | — | — | 2 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 1 | — | — | — | 1 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | 1 | — | — | — | 1 |
Show 12 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv seropositivity | D006679 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | — | — | — | — | 2 | 2 |
| Inflammation | D007249 | MP_0001845 | — | — | — | — | — | 1 | 1 |
| Healthy volunteers/patients | — | — | — | — | — | — | — | 1 | 1 |
| Hiv-2 | D015498 | — | — | — | — | — | — | 1 | 1 |
| Immunologic deficiency syndromes | D007153 | HP_0002721 | D84.9 | — | — | — | — | 1 | 1 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | — | — | 1 | 1 |
| Sleep apnea syndromes | D012891 | HP_0010535 | G47.3 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Tesamorelin |
| INN | tesamorelin |
| Description | Tesamorelin (INN) (trade name Egrifta) is a synthetic form of growth-hormone-releasing hormone (GHRH) which is used in the treatment of HIV-associated lipodystrophy, approved initially in 2010. It is produced and developed by Theratechnologies, Inc. of Canada. The drug is a synthetic peptide consisting of all 44 amino acids of human GHRH with the addition of a trans-3-hexenoic acid group.
|
| Classification | Peptide |
| Drug class | prehormones or hormone-release stimulating peptides: growth hormone-release stimulating peptides |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1237026 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | MQG94M5EEO (ChemIDplus, GSRS) |
Target
Agency Approved
GHRHR
GHRHR
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 245 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,873 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use